ReviewClinical reviews in allergy & immunology2025
A Multisectoral Study of Mpox Epidemiology, Resistance Surveillance, and Policy Gaps: Toward a One Health Framework.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox, formerly known as monkeypox, has recently spread beyond its traditional epidemic areas. Several regions of Africa have been affected and have become a health concern globally. This review presents epidemiology, clinical symptoms, diagnostic developments, treatment methods, and policy gaps of Mpox. Methodologically, this review incorporates data from over 70 peer-reviewed journal articles, official epidemiological bulletins, and curated surveillance datasets from WHO, CDC, and PubMed to provide an evidence-based analysis of Mpox. As all data were derived from secondary sources, no sampling method was utilized. Firstly, we examined the primary causes of the virus's resurgence, including zoonotic spillover, human-to-human transmission, and globalization, which contribute to the spread of Mpox disease. Next, we discussed different treatment alternatives for Mpox, such as Tecovirimat and JYNNEOS vaccination, diagnostic techniques including polymerase chain reaction (PCR), serological tests, and new point-of-care diagnostics based on clustered regularly interspaced short palindromic repeats (CRISPR). Then, we highlighted the public health challenges of Mpox, including misdiagnosis, healthcare disparities, and the impact on immunosuppressed populations, particularly HIV-positive individuals. Finally, this study discussed the socioeconomic implications of Mpox outbreaks, emphasizing the need for global collaboration, enhanced surveillance, and robust vaccination programs to minimize future outbreaks.
Indexed as
Identifiers
41428319What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.